aibioSarepta Therapeutics SRPT class action, offering and convertible notes news
Top story · Sep 23, 2026 · aibio.space
Sarepta faces securities class action and five derivative suits over Elevidys disclosures
The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026.
- Ticker
- SRPT
- Listing
- NASDAQ, United States
- Next date
- 2H 2026
- Chief executive
- Michael Severino, M.D.
Desk view · Opinion · Updated Oct 22, 2026
Sarepta's next chapter depends on siRNA data, not Elevidys
Sarepta is a near-breakeven Duchenne company whose gene therapy has shrunk and whose older drugs face an FDA ruling in February 2027. The investment case now rests on whether the Arrowhead siRNA platform works in DM1 and FSHD with repeat dosing, which the company says it will show in the second half of 2026.
Read the full desk viewaibio.space Investor Rank · Opinion
2/10 Most negative view
Elevidys has shrunk under a boxed warning and the exon skippers face an FDA ruling, so the case rests on early siRNA data in DM1 and FSHD.
- Technology
- 1/2
- Odds
- 0/2
- Balance sheet
- 1/2
- Risk
- 0/2
- Momentum
- 0/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven in Duchenne, unproven beyond. Exon skippers and Elevidys are approved; the Arrowhead siRNA platform has only single-dose data showing dose-dependent muscle delivery.
- Odds
- Early stage for the growth story. The siRNA programs are in phase 1/2, where rare disease drugs reach approval about 17% of the time per BIO data.
- Balance sheet
- Adequate for now. About $945 million in cash against $848 million in convertible notes, with the company near breakeven on a non-GAAP basis.
- Main risk
- Two franchises under pressure. Elevidys has a boxed warning, and the exon-skipping drugs face an FDA ruling after a missed confirmatory endpoint.
- Watch next
- DM1 and FSHD repeat-dose data. Readouts are due in the second half of 2026, followed by the Feb. 28, 2027 FDA action date.
Top news on Sarepta
- Legal
Sarepta faces securities class action and five derivative suits over Elevidys disclosures
The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026.
- Financings
Sarepta agrees to swap about $700.0 million of 2027 convertible notes, sell $20.0 million of stock
Sarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber.
Questions investors ask
What is aibio.space's Investor Rank for Sarepta Therapeutics?
2 out of 10, our most negative view. Elevidys has shrunk under a boxed warning and the exon skippers face an FDA ruling, so the case rests on early siRNA data in DM1 and FSHD. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
Why did Sarepta's Elevidys sales fall in 2026?
In November 2025 the FDA limited Elevidys to ambulatory patients and added a boxed warning for acute liver failure after two deaths in non-ambulatory boys. Elevidys revenue was $98.1 million in Q2 2026, down from $102.0 million in Q1. Source
Who is Sarepta's new CEO?
Michael Severino, a former vice chairman and president of AbbVie and CEO of Tessera Therapeutics, became Sarepta's CEO on July 28, 2026. Doug Ingram retired and is advising the company through the end of 2026. Source
When will the FDA decide on full approval of Vyondys 53 and Amondys 45?
The FDA set a target action date of Feb. 28, 2027 for Sarepta's applications to convert both drugs from accelerated to traditional approval. The filings cite the ESSENCE study, which missed its primary endpoint, and real-world evidence. Source
How much cash does Sarepta have?
Sarepta reported $945.0 million in cash, cash equivalents, restricted cash and investments at June 30, 2026. It said resources are enough to fund its operating plan for at least 12 months. Source
When are Sarepta's DM1 and FSHD siRNA results due?
Sarepta said multiple-ascending-dose readouts from the phase 1/2 studies of SRP-1003 in DM1 and SRP-1001 in FSHD1 are on track for the second half of 2026. Single-dose data shown in March 2026 reported dose-dependent drug levels in muscle. Source
What is the latest Sarepta Therapeutics (SRPT) stock news?
Our latest story on Sarepta Therapeutics, dated Sep 23, 2026: "Sarepta faces securities class action and five derivative suits over Elevidys disclosures". The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026. Source
What is Sarepta Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Aug 21, 2025: "Sarepta agrees to swap about $700.0 million of 2027 convertible notes, sell $20.0 million of stock". Sarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber. Source
Who were the underwriters or placement agents on Sarepta Therapeutics's offering?
From our story: It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber. Source
How much cash does Sarepta Therapeutics have?
From our story of Aug 21, 2025: Sarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. Source
Is Sarepta Therapeutics facing a lawsuit?
Our latest legal story, dated Sep 23, 2026: "Sarepta faces securities class action and five derivative suits over Elevidys disclosures". The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026. Claims in lawsuits are allegations until a court rules. Source
What is Sarepta Therapeutics's market cap?
We do not publish live share prices. In its annual report, Sarepta Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $1.67 billion as of Jun 30, 2025. Source
Is Sarepta Therapeutics a smaller reporting company?
SEC records list Sarepta Therapeutics, Inc.'s filer category as: Large accelerated filer. Source
Where is Sarepta Therapeutics headquartered?
SEC records list its business address as 215 FIRST STREET, CAMBRIDGE, MA, 02142. Source
When does Sarepta Therapeutics's fiscal year end?
Sarepta Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records. Source
Legal and investor matters
- Litigation
Sarepta settles REGENXBIO and UPenn patent suits over ELEVIDYS for $39.0 million
On 2026-09-23 Sarepta, REGENXBIO, the University of Pennsylvania and Catalent signed a settlement agreement resolving pending patent infringement litigations and an appeal from inter partes review proceedings relating to the 274 and 617 patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million within ten days. REGENXBIO and UPenn released Sarepta and Catalent from infringement claims on AAVrh74-based gene therapy products, including ELEVIDYS, up to the effective date.
- Class action
Oral argument held on Sarepta motion to dismiss amended securities complaint
Sarepta reported in its 10-Q filed 2026-08-05 that oral argument on its motion to dismiss the amended securities class action complaint was held on 2026-08-04 in the District of Massachusetts. The defendants filed the motion on 2026-03-09. The case was moved from the Southern District of New York to Massachusetts after the court granted a transfer motion on 2025-11-06.
- Derivative suit
Second Massachusetts derivative suit filed against Sarepta directors and officers
The 10-Q filed 2026-08-05 says a second shareholder derivative suit was filed on 2026-07-23 in the District of Massachusetts, with Sarepta as nominal defendant. It names nearly all the directors and officers sued in the first Massachusetts case, drops Dallan Murray and adds Ian Estepan. The court had stayed the first case on 2026-06-22 until the securities action is resolved, and the stay terms apply to later-filed derivative suits.
- Governance
Sarepta names Michael Severino chief executive; Douglas Ingram departs
Sarepta said its board appointed Michael Severino chief executive officer and a Class I director effective 2026-07-28. He succeeds Douglas Ingram, who left the CEO role and the board that day and will consult for Sarepta until 2026-12-31 at $15,000 a month. Severino most recently led Tessera Therapeutics. Ingram had told the company on 2026-02-25 that he planned to retire.
- Derivative suit
Massachusetts shareholder derivative suit filed against Sarepta directors and officers
A shareholder derivative suit was filed on 2026-04-07 in the District of Massachusetts against the same directors and officers named in the New York derivative case, with Sarepta as nominal defendant. The 10-Q filed 2026-08-05 says it rests on similar statements as the securities action and adds allegations about the 2025 proxy statement, the November 2024 stock repurchase and director stock sales. The court stayed it on 2026-06-22.
- Governance
Sarepta CEO Douglas Ingram says he will retire by end of 2026
In an 8-K dated 2026-02-25, Sarepta said chief executive Douglas Ingram notified the company of his decision to retire by the end of 2026 or when a replacement is appointed. The company said it had started a search of internal and external candidates. The filing gives no reason beyond the retirement decision.
- Litigation
Federal Circuit revives REGENXBIO patent suit against Sarepta over ELEVIDYS
The Federal Circuit on 2026-02-20 reversed the District of Delaware ruling that REGENXBIO and UPenn patent claims covering host cells for AAV gene therapy were invalid, and sent the case back for further proceedings. Sarepta sought rehearing en banc on 2026-03-23, which was denied 2026-04-22, and the mandate issued 2026-04-29. The parties settled this suit on 2026-09-23.
- Class action
Amended Sarepta securities complaint widens class period and adds defendant
On 2026-01-22 lead plaintiffs filed an amended complaint in the Sarepta securities class action. It adds Ian Estepan as a defendant, removes Dallan Murray, and extends the class period to 2023-06-22 through 2025-11-03. The complaint alleges false or misleading statements about ELEVIDYS and LGMD therapy safety, the status of LGMD development and the ESSENCE trial.
- Financing
Sarepta swaps $291.4 million of 2027 converts for 2030 notes, with director-linked holder
On 2025-12-10 Sarepta agreed with some holders of its 1.25% convertible notes due 2027 to exchange about $291.4 million of principal for the same amount of new 4.875% convertible notes due 2030, plus about $31.6 million in cash. Holders included the Michael A. Chambers Living Trust, which is affiliated with director Michael Chambers. The new notes were issued 2025-12-18.
- Financing
Sarepta exchanges $700 million of 2027 converts for 2030 notes, shares and cash
On 2025-08-20 Sarepta agreed with holders of its 1.25% convertible notes due 2027 to exchange $700.0 million of principal for $602.0 million of new 4.875% convertible notes due 2030, 5,851,693 common shares and about $123.3 million in cash. The new notes were issued 2025-08-28 and mature 2030-09-01.
- Regulatory
FDA places clinical hold on Sarepta LGMD gene therapy trials
Sarepta announced on 2025-07-21 that the FDA placed a clinical hold on its limb girdle muscular dystrophy gene therapy trials, covering SRP-9003, SRP-9004, SRP-6004 and SRP-9005. The same day it said the FDA revoked the platform technology designation for its AAVrh74 platform, granted on 2025-06-02. Sarepta had paused all those programs except SRP-9003 on 2025-07-16.
- Other
Sarepta cuts about 36% of workforce in restructuring
On 2025-07-16 Sarepta disclosed a restructuring with a revised cost structure and program portfolio. Its board approved on 2025-07-14 a reduction in force of about 36% of the workforce. The company estimated a one-time third-quarter charge for termination benefits of roughly $32 million to $37 million, all in cash.
- Derivative suit
Shareholder derivative suits filed in New York against Sarepta directors and officers
A shareholder derivative suit was filed 2025-07-15 in the Southern District of New York against Sarepta directors and several officers, naming Sarepta as nominal defendant. Two similar suits followed on 2025-08-20 and 2025-09-10. The court consolidated them on 2025-10-10 and stayed the case on 2025-11-17 until the securities action is resolved. The complaints allege breaches of fiduciary duty and Section 14(a) violations tied to the 2024 and 2025 proxy statements.
- Class action
Securities class action filed against Sarepta and executives over ELEVIDYS disclosures
A putative securities class action was filed 2025-06-26 in the Southern District of New York against Sarepta, then-CEO Douglas Ingram, Dallan Murray and Louise Rodino-Klapac. The complaint alleges Exchange Act and Rule 10b-5 violations in disclosures about ELEVIDYS safety and efficacy and the financial statements and projections. The proposed class bought stock from 2023-06-22 to 2025-06-24. The court appointed lead plaintiffs 2025-10-17, and the case moved to Massachusetts on 2025-11-06.
- Litigation
Genzyme patent suit over ELEVIDYS adds five patents; trial set for 2027
Genzyme sued Sarepta in the District of Delaware on 2024-07-26, alleging ELEVIDYS infringes two patents and seeking damages including treble damages. On 2025-05-27 the court let Genzyme add five more patents. Trial is set for 2027-06-14. The 10-Q filed 2026-08-05 says the USPTO director instituted inter partes review of the 894 patent and denied it for four others, with oral argument set for 2027-02-04.
- Financing
Sarepta signs $600 million secured revolving credit facility with JPMorgan
On 2025-02-13 Sarepta and a subsidiary signed a credit agreement with JPMorgan Chase Bank as administrative and collateral agent. It provides a five-year, $600 million senior secured revolving credit facility with variable rates based on SOFR plus a margin of 1.125% to 1.75%. The facility does not amortize and matures on the fifth anniversary of the closing date.
- Litigation
Judgment entered on jury verdict in Sarepta patent case against Nippon Shinyaku
After a December 2024 jury trial in the District of Delaware, the jury found Nippon Shinyaku's 092 patent invalid as obvious and Sarepta and UWA's 851 patent not invalid. It awarded Sarepta about $115.2 million for Viltepso sales in the United States through 2024-12-15, and the parties stipulated about $0.8 million for sales outside the United States. Judgment was entered 2025-01-07, and post-trial motions remain pending.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Elevidys (delandistrogene moxeparvovec) | Duchenne muscular dystrophy, ambulatory patients aged 4 and older | Approved (US), boxed warning since Nov 2025 Source |
| Vyondys 53 and Amondys 45 | Duchenne muscular dystrophy, exon 53 and exon 45 amenable | Accelerated approval; sNDAs for traditional approval under FDA review Source |
| Elevidys with sirolimus (ENDEAVOR Cohort 8) | Non-ambulatory Duchenne muscular dystrophy | Clinical study, dosing began April 2026 Source |
| SRP-1003 (siRNA) | Myotonic dystrophy type 1 | Phase 1/2 Source |
| SRP-1001 (siRNA) | Facioscapulohumeral muscular dystrophy type 1 | Phase 1/2 Source |
| SRP-1005 (siRNA) | Huntington's disease | Phase 1 (INSIGHTT), dosing underway Source |
Opinion · Devil's advocate
Fact-check-o-meter
Sarepta's upbeat second-quarter release is softer on ESSENCE and Elevidys risks than its 10-Q
The August release presents the exon-skipping drugs' regulatory filings as supported by the ESSENCE confirmatory study and calls the balance sheet strong. The 10-Q says ESSENCE missed its primary endpoint, warns that accelerated approvals could be revoked, and limits its funding statement to the next twelve months. Litigation is extensive and described in the 10-Q, including a securities class action.
Press release vs filing · weight high
Release cites ESSENCE as support; the 10-Q says it missed its primary endpoint
The company said: "The applications are supported by data from the ESSENCE confirmatory study, substantial published real-world evidence, and the favorable, consistent safety profiles of both exon-skipping therapies." source
The record says: The 10-Q states: "In November 2025, we announced topline results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of two of our PMO Products: AMONDYS 45 and VYONDYS 53. The topline results did not show statistical significance on the study's primary endpoint." Its liquidity risk list names "revocation of accelerated approvals and directives to remove products from the market relating to the topline results of our ESSENCE trial that failed to meet statistical significance on its primary endpoint." source
Our view: The release's only mention of ESSENCE is as a source of support. It does not say the trial missed. The 10-Q is where an investor learns that the confirmatory study failed its primary endpoint and that withdrawal of the accelerated approvals is a disclosed risk. The FDA decision on the sNDAs is the event that settles this.
Press release vs filing · weight medium
"Strong financial position" versus a twelve-month funding statement
The company said: "Strong financial position supports advancement of our pipeline and funding of medium-term liabilities" source
The record says: The 10-Q says cash, investments and operating cash flows are "sufficient to fund its current operational plan for at least the next twelve months," and that "Beyond June 30, 2027, our cash requirements will depend extensively on our ability to advance our research, development and commercialization of product candidates." It lists "the obligations to holders of our 2027 Notes and 2030 Notes" and the ability to "resume commercial shipments of ELEVIDYS for non-ambulatory patients" among the factors. The release reports GAAP operating income of $13.3 million against non-GAAP $86.5 million; the release defines non-GAAP as excluding depreciation, stock compensation and the litigation contingency charge, and the 10-Q records that charge at $39.0 million. source
Our view: $945.0 million of cash is real and the company had GAAP operating income of $13.3 million in the quarter, but a GAAP net loss of $4.9 million. Total revenue fell to $401.3 million from $611.1 million a year earlier, and the 10-Q does not extend its funding comfort past a year.
Science · weight medium
Elevidys non-ambulatory restart depends on a single-arm cohort and FDA agreement
The company said: "For ELEVIDYS, full enrollment of ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027." source
The record says: The 10-Q says: "Resumption of dosing in the non-ambulatory population will depend on the FDA's analysis of whether the sirolimus data positively changes ELEVIDYS' risk/benefit profile and on aligning with the FDA on the process for revising the label, both of which involve risks and uncertainties." ClinicalTrials.gov lists the ENDEAVOR study (NCT04626674) as an unmasked Phase 1 with an estimated 83 participants; its Cohort 8 primary outcome is "Number of Participants with Acute Liver Injury (ALI)" up to Week 72, plus dystrophin expression at Week 12. source
Our view: The release gives the data timing but not what the data must show to restart dosing. A small unmasked cohort with a liver injury count as a primary outcome can inform safety, but it will not show clinical benefit. The label now carries a boxed warning for acute liver injury.
Science · weight high
ESSENCE was a large, masked trial on a functional endpoint
The record says: ClinicalTrials.gov lists ESSENCE (NCT02500381) as a Phase 3, quadruple-masked study with 228 participants enrolled and a single primary outcome of "Change From Baseline in the 4-Step Ascend Velocity at Week 96." Dystrophin protein levels by Western blot are listed as a secondary outcome. The 10-Q says the study missed statistical significance on its primary endpoint and that Sarepta submitted sNDAs for traditional approval in April 2026, accepted for filing in June 2026. source
Our view: This was the proper randomized test of whether the dystrophin-based accelerated approvals translate into function. The sNDAs lean on real-world evidence and safety instead. Whether FDA accepts that mix is the open question.
Legal and disclosure record · weight high
Securities class action, derivative suits and patent cases are pending
The record says: Note 16 of the 10-Q describes a putative securities class action filed June 26, 2025 in the U.S. District Court for the Southern District of New York and transferred to the District of Massachusetts on November 6, 2025. The amended complaint covers purchasers between June 22, 2023 and November 3, 2025 and alleges statements about Elevidys safety, the LGMD programs and the ESSENCE trial were false or misleading. Sarepta moved to dismiss on March 9, 2026, and oral argument was held August 4, 2026. Derivative suits were filed in S.D.N.Y. (July 2025, stayed) and D. Mass. (April 7 and July 23, 2026). Patent suits by REGENXBIO and the University of Pennsylvania, Nippon Shinyaku and Genzyme are disclosed, with a Genzyme trial scheduled for June 14, 2027, and a $39.0 million charge for a potential patent settlement still subject to documentation. source
Our view: These are allegations in court filings that the company is contesting. No ruling on the motion to dismiss is disclosed. The ruling on the motion and the patent settlement paperwork are the next items to follow.
Stock chart
SEC filings and registration
- SEC name
- Sarepta Therapeutics, Inc.
- CIK
- 873303
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- SRPT (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 215 FIRST STREET, CAMBRIDGE, MA, 02142
- Phone
- 617-274-4000
- Shares outstanding
- 105,627,021 as of 2026-07-31 (10-Q filed 2026-08-05)
- Former names
- Sarepta Therapeutics, Inc.; AVI BIOPHARMA INC; ANTIVIRALS INC
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction